Attributes | Values |
---|
rdf:type
| |
Description
| - Background & Aims Peginterferon plus ribavirin has been the standard of care for chronic hepatitis C for a decade and an essential component of combination regimens for this disease. This large multinational open-label study aimed to better define the incidence of serious adverse events (SAEs) and non-serious adverse events of special interest in patients receiving peginterferon alfa-2a/ribavirin. Methods Patients were assigned at the investigator's discretion to 24- or 48-week treatment with peginterferon alfa-2a 180 mmg/week and ribavirin 800 mg/day or 1000/1200 mg/day. All AEs, defined as SAEs and non-SAEs of special interest, were recorded during treatment and for 12 weeks thereafter. Non-SAEs of special interest included those leading to dose reduction/discontinuation, neutropenia, thrombocytopenia, anaemia, ALT elevations leading to dose modification and unknown/unexpected AEs. Results Of 1675 and 7178 patients assigned to 24 and 48 weeks of treatment, respectively, 87.6 and 68.
- Background & Aims Peginterferon plus ribavirin has been the standard of care for chronic hepatitis C for a decade and an essential component of combination regimens for this disease. This large multinational open-label study aimed to better define the incidence of serious adverse events (SAEs) and non-serious adverse events of special interest in patients receiving peginterferon alfa-2a/ribavirin. Methods Patients were assigned at the investigator's discretion to 24- or 48-week treatment with peginterferon alfa-2a 180 mmg/week and ribavirin 800 mg/day or 1000/1200 mg/day. All AEs, defined as SAEs and non-SAEs of special interest, were recorded during treatment and for 12 weeks thereafter. Non-SAEs of special interest included those leading to dose reduction/discontinuation, neutropenia, thrombocytopenia, anaemia, ALT elevations leading to dose modification and unknown/unexpected AEs. Results Of 1675 and 7178 patients assigned to 24 and 48 weeks of treatment, respectively, 87.6 and 68. (en)
|
Title
| - Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
- Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients (en)
|
skos:prefLabel
| - Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
- Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients (en)
|
skos:notation
| - RIV/00216224:14110/12:00061655!RIV13-MSM-14110___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216224:14110/12:00061655
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - chronic hepatitis C; pegylated interferon; ribavirin; treatment (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Husa, Petr
- Ferenci, Peter
- Berak, Hanna
- Dusheiko, Geoffrey M.
- Gane, Edward J.
- Hadziyannis, Stephanos J.
- Han, Kwang-Hyub
- Harley, Hugh A.
- Heathcote, Jenny E.
- Horsmans, Yves J.
- Lee, Samuel S.
- Messinger, Diethelm
- Roberts, Stuart K.
- Tatsch, Fernando
|
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |
http://bibframe.org/vocab/doi
| - 10.1111/j.1478-3231.2012.02819.x
|
http://localhost/t...ganizacniJednotka
| |